Ascendis Pharmaの空売り状況は、投資家がAscendis Pharmaの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Ascendis Pharma (NASDAQ:ASND) 株価情報, 空売り情報

Ascendis Pharma

Ascendis Pharma AS is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma AS

TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Buy and lowers the price target from $160 to $153.

News

Price Target

Analyst Ratings

ASND

TD Cowen Maintains Buy on Ascendis Pharma, Lowers Price Target to $153

Wedbush analyst Andreas Argyrides reiterates Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Outperform and maintains $181 price target.

Reiteration

Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $181 Price Target

WIIM

Acendis Pharma shares are trading higher after Stifel maintained a Buy rating on the stock and raised its price target from $200 to $207.

Oppenheimer analyst Leland Gershell maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Outperform and lowers the price target from $190 to $180.

Oppenheimer Maintains Outperform on Ascendis Pharma, Lowers Price Target to $180

Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Overweight and maintains $170 price target.

Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $170 Price Target

Stifel analyst Alex Thompson maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Buy and raises the price target from $200 to $207.

Stifel Maintains Buy on Ascendis Pharma, Raises Price Target to $207

Guidance

Ascendis Sees FY24 Operating Expenses ~€600M

Ascendis Pharma shares are trading lower. The company reported Q3 financial results.

Earnings

Ascendis Q3 2024 Revenue $€57.8M Vs €48M Prior

Ascendis Pharma's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NYSE">ASND</a>) short percent of float has risen 5.52% since its last report. The company recently reported that it has 3.41 million shares sold short, which is 8.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 11.21 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ascendis Pharma Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731604512_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ascendis Pharma has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ascendis Pharma's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ascendis Pharma's peer group average for short interest as a percentage of float is 11.13%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

(ASND) - Analyzing Ascendis Pharma's Short Interest

AFMD

AGAE

AIRI

AKYA

AMAT

AQMS

AREC

ASTS

AZUL

BENF

BILI

BIOR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BKTI

BKYI

BLUE

BNAI

BNZI

BRAG

BTAI

CASI

CELC

CINT

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNVS

CRIS

CWCO

DARE

DBGI

DESP

DFLI

DLPN

DMRC

DNMR

DPRO

DTST

EAST

EFXT

ELUT

EWCZ

FLNT

FTLF

GAMB

GAME

GCTS

GDEV

GLOB

HYLN

IMCC

INKT

INTR

ITRM

IVVD

IZEA

LCTX

LIQT

LOCL

LUNR

MITQ

MOVE

MSGM

MUFG

NICE

NOMD

NTES

OCFT

OCUL

OKLO

ONEW

ORGN

PDSB

PHGE

POCI

POST

Earnings Scheduled For November 14, 2024

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) is preparing to release its quarterly earnings on Thursday, 2024-11-14. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Ascendis Pharma to report an earnings per share (EPS) of $-1.66.
Ascendis Pharma bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS missed by $0.50, leading to a 11.27% drop in the share price on the subsequent day.
Here's a look at Ascendis Pharma's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.56</td>
<td></td>
<td>-2.15</td>
<td>-2.75</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-2.06</td>
<td>-2.5</td>
<td>-1.66</td>
<td>-3.13</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-11.0%</td>
<td>-3.0%</td>
<td>-0.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<h3>Performance of Ascendis Pharma Shares</h3>
Shares of Ascendis Pharma were trading at $127.67 as of November 12. Over the last 52-week period, shares are up 36.55%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ASND/earnings">To track all earnings releases for Ascendis Pharma visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse of Ascendis Pharma's Earnings Potential

Novo Nordisk AS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) will report third-quarter earnings on Wednesday. Wall Street expects 88 cents in EPS and $10.49 billion in revenues when the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=NVO" target="_blank" rel="noreferrer noopener"> after market hours</a>. 
The stock is up 8.55% over the last year and 7.45% year-to-date.
Let&#8217;s look at what the charts indicate for Novo Nordisk stock and how the stock maps against Wall Street estimates.
<h2 class="wp-block-heading">Novo Nordisk Stock Chart Bearish Ahead Of Q3 Earnings</h2>
Novo Nordisk&#8217;s stock is showing strong bearish momentum, as its price of $108.76 sits below its five- 20- and 50-day exponential moving averages. This downward trend is accompanied by persistent selling pressure, suggesting potential for continued bearish movement.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="625" height="454" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05081610/Screenshot-2024-11-05-at-6.30.26-PM.png" alt="" class="wp-image-630249" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05081610/Screenshot-2024-11-05-at-6.30.26-PM.png 625w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05081610/Screenshot-2024-11-05-at-6.30.26-PM-300x218.png 300w" sizes="(max-width: 625px) 100vw, 625px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
With an eight-day simple moving average (SMA) of $111.67, a 20-day SMA of $115.16 and a 50-day SMA of $123.13 — all above the current price — technical indicators point to a bearish signal for NVO stock.
Additionally, the 200-day SMA at $128.29 further underscores the bearish outlook. 
The Moving Average Convergence Divergence (MACD) indicator at a negative 3.44 signals downside momentum, while a Relative Strength Index (RSI) of 25.06 indicates oversold conditions, hinting that NVO stock may face further declines without substantial support or a shift in buying interest.
Read Also: <a href="https://www.benzinga.com/general/biotech/24/11/41685634/popular-weight-loss-drug-wegovy-shows-encouraging-results-in-liver-fibrosis-trial">Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial</a>
<h2 class="wp-block-heading">New Partnership For Longer-Acting GLP-1 Drugs</h2>
In a significant move to broaden its portfolio, Novo Nordisk has entered into <a href="https://www.benzinga.com/general/biotech/24/11/41723496/wegovy-manufacturer-inks-multi-million-deal-for-monthly-obesity-drug">a $285 million agreement</a> with Denmark-based Ascendis Pharma AS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>). This partnership grants Novo exclusive worldwide rights to Ascendis' TransCon technology, aiming to develop once-monthly GLP-1 receptor agonists for Type 2 diabetes and obesity — a step up from its weekly GLP-1 drugs.
The alliance also covers cardiovascular diseases, with Novo retaining the option to expand future metabolic treatments into additional therapeutic areas. Ascendis will lead early-stage development, while Novo handles the regulatory, manufacturing, and commercial phases.
The lead program in the partnership is a once-monthly GLP-1 drug, a potential game-changer for patients with metabolic disorders. Novo's recent clinical studies underscore the broader health impact of its GLP-1 treatments, showing reduced hospital admissions for heart disease in overweight patients, boosting investor confidence in the potential cardiovascular applications of the new drug.
<h2 class="wp-block-heading">Novo Nordisk Analysts See 46% Upside</h2>
<a href="https://www.benzinga.com/quote/NVO/analyst-ratings" target="_blank" rel="noreferrer noopener">The consensus analyst rating</a> on Novo Nordisk stock stands at a Buy with a price target of $123.86. The latest analyst ratings for Novo Nordisk stock from BMO Capital and Cantor Fitzgerald give an average price target of $158.67, suggesting 45.78% upside potential.
As Novo Nordisk readies to share its third-quarter performance, the dual narratives of bearish technicals and bullish analyst ratings, combined with a groundbreaking new partnership, make the upcoming earnings call a highly anticipated event.
Price Action: Novo Nordisk stock closed the trading day Monday at $109.72, down 1.98%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41706292/as-race-to-best-miracle-obesity-drug-heats-up-ozempic-maker-novo-nordisk-tests-new-hybrid-drug-th">As Race To Best &#8216;Miracle&#8217; Obesity Drug Heats Up, Ozempic Maker Novo Nordisk Tests New Hybrid Drug That Can Reduce Weight Up To 25%</a></li>
</ul>
Image: Shutterstock

Biotech

Health Care

Technicals

Previews

General

Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?

On Monday, Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) granted Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) an <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41709477/ascendis-pharma-and-novo-nordisk-sign-collaboration-for-development-and-commercialization-of-trans" rel="noreferrer noopener">exclusive worldwide license</a>.
The pact will focus on the TransCon technology platform to develop, manufacture, and commercialize Novo Nordisk proprietary products for metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license for cardiovascular diseases.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40882593/ascendis-pharmas-rare-dwarfism-candidate-shows-promise-in-trial-fda-submission-expected-next-year" rel="noreferrer noopener">Ascendis Pharma&#8217;s Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year</a>
The agreement includes provisions requiring certain TransCon technology-based products to be identified and advanced in metabolic diseases to maintain exclusivity in the field and additional provisions for cardiovascular diseases.
Under the terms of the agreement, Novo Nordisk also receives exclusive rights to expand any resulting metabolic disease products into other therapeutic areas.
The lead program in the collaboration is a once-monthly GLP-1 receptor agonist product candidate that will initially target obesity and type 2 diabetes.
Ascendis will be eligible to receive total payments of up to $285 million in upfront, development, and regulatory milestone payments for the lead program.
In addition, Ascendis will be eligible to receive sales-based milestone payments and tiered royalties on global net sales.
For each additional metabolic or cardiovascular disease product candidate, Ascendis will be eligible to receive payments of up to $77.5 million in development and regulatory milestone payments, plus sales-based milestone payments and tiered royalties on global net sales.
Ascendis will conduct early development of TransCon product candidates in collaboration.
Novo Nordisk will be responsible for these early development costs, clinical development, regulatory, commercial manufacturing, and commercialization.
&#8220;The agreement with Novo Nordisk reflects our Vision 2030 to create value in additional large therapeutic areas outside endocrinology rare disease through collaborations with established global leaders,&#8221; said Jan Mikkelsen, Ascendis Pharma&#8217;s President and CEO.
&#8220;We look forward to working with Ascendis to explore the potential of the TransCon technology platform to reduce the dosing frequency of GLP-1 receptor agonists and other treatments for cardiometabolic diseases,&#8221; said Brian Vandahl, Senior Vice President of Global Research Technologies at Novo Nordisk.
The transaction is expected to close before the end of 2024.
Price Action: At the last check on Monday, ASND stock was up 1.91% at $127.67, and NVO stock was down 1.61% at $110.14.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41720697/totalenergies-bolsters-lng-presence-in-china-with-15-year-supply-deal-details" target="_blank" rel="noreferrer noopener">TotalEnergies Bolsters LNG Presence In China With 15-Year Supply Deal: Details</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Large Cap

Contracts

Movers

Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) has outperformed the market over the past 15 years by 19.45% on an annualized basis producing an average annual return of 31.06%. Currently, Ascendis Pharma has a market capitalization of $7.49 billion. 
Buying $100 In ASND: If an investor had bought $100 of ASND stock 15 years ago, it would be worth $5,581.08 today based on a price of $125.28 for ASND at the time of writing.
<h3>Ascendis Pharma's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730739621_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 15 Years Ago, You Would Have $5,600 Today

Ascendis has granted Novo Nordisk A/S an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases.
In exchange for the license, Ascendis will be eligible to receive total payments of up to $285 million in upfront, development, and regulatory milestone payments for the lead program.&nbsp;
In addition, Ascendis will be eligible to receive sales-based milestone payments and tiered royalties on global net sales. For each additional metabolic or cardiovascular disease product candidate, Ascendis will be eligible to receive payments of up to $77.5 million in development and regulatory milestone payments, plus sales-based milestone payments and tiered royalties on global net sales.
The closing of this transaction is subject to receipt of applicable regulatory approvals and the parties are seeking to close before the end of 2024.
 &nbsp;

Ascendis Pharma, Novo Nordisk Partner For Development, Commercialization Of TransCon Technology-Based Products In Metabolic, Cardiovascular Diseases; Ascendis To Be Eligible To Receive Payments Of Up To $285M For Lead Program

On Tuesday, Biomarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) <a href="https://www.benzinga.com/earnings">reported third-quarter</a> adjusted EPS of 91 cents, almost double the 46 cents reported a year ago, beating the consensus of 52 cents.
The company reported sales of $745.74 million, beating the consensus of $700.14 million. Sales increased 28%, driven by strong VOXZOGO contributions from new <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41610287/biomarin-announces-28-yy-total-revenue-growth-in-the-third-quarter-and-increase-in-full-year-2024-" rel="noreferrer noopener">patient starts in all regions</a>.
In the quarter, revenues from BioMarin&#8217;s Enzyme Therapies (Vimizim, Naglazyme, Aldurazyme, Brineura, and Palynziq) increased 27% year over year.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41033938/biomarin-stands-firm-on-2027-revenue-target-amid-ascendis-competition-goldman-sachs" rel="noreferrer noopener">BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish</a>
Guidance: BioMarin reaffirmed its long-term guidance and outlook, targeting around $4 billion in revenues in 2027.
The company expects a 40% adjusted operating margin starting in 2026 and growing to the low-to mid-40% range over time.
William Blair has downgraded <a target="_blank" href="https://www.benzinga.com/quote/BMRN/analyst-ratings" rel="noreferrer noopener">BioMarin to a Market Perform</a>.
The analyst adds, &#8220;We believe the company&#8217;s current valuation adequately reflects revenue estimates for the company&#8217;s commercial portfolio, and we do not think its clinical pipeline will be a source of significant value creation in the near term.&#8221;
William Blair models 2024 and 2025 revenue of $2.8 billion and $3.1 billion, respectively.
Voxzogo sales increased 54% to $190 million in the third quarter. The analyst says Voxzogo remains the company&#8217;s key topline growth driver, but the threat of competition could erode its revenue growth and market share.
Last month, Ascendis Pharma A/S&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) released topline data from a trial in achondroplasia, showing its long-acting CNP, navepegritide, could potentially deliver similar efficacy as Voxzogo but with a more attractive once-weekly dosing.
Although Voxzogo&#8217;s label might expand, William Blair does not anticipate a significant increase in the total addressable patient population until 2030.
Despite BioMarin&#8217;s strong pipeline, the analyst does not consider data readouts from its early-stage programs over the next year as significant value drivers.
Only two programs are expected to contribute to BioMarin&#8217;s top line through label expansions by 2027: Palynziq for adolescent Phenylketonuria (PKU) patients and Voxzogo for Hypochondroplasia&nbsp;(HCH).
Analyst Reaction:
<ul>
<li>Baird maintains Biomarin and lowers the price target from $72 to $65.</li>
<li>UBS reaffirms the Buy rating, raising the price target from $104 to $106.</li>
<li>Evercore ISI maintains Biomarin with an Outperform rating, lowering the price target from $115 to $105.</li>
<li>RBC Capital reiterates Biomarin with a Sector Perform and price target of $80.</li>
</ul>
Price Action: BMRN stock is down 3.1% at $67.74 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41629194/wingstop-q3-eps-misses-as-chicken-wing-costs-bite-strong-sales-growth-aggressive-expansion-plans-mo" target="_blank" rel="noreferrer noopener">Wingstop Q3: EPS Misses As Chicken Wing Costs Bite, Strong Sales Growth, Aggressive Expansion Plans &amp; More</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Downgrades

BMRN

BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth

JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Overweight and lowers the price target from $180 to $174.

JP Morgan Maintains Overweight on Ascendis Pharma, Lowers Price Target to $174

TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Buy and raises the price target from $157 to $160.

TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $160

In a report released yesterday, Derek Archila from Wells Fargo maintained a Buy rating on Ascendis Pharma (ASND – Research Report), with a price ta...

Ascendis Pharma's Strategic Advances and Yorvipath Launch Position Stock for Growth: Buy Rating Affirmed by Analyst

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Ascendis Pharma (ASND – Research Report), with a price target of ...

Buy Rating for Ascendis Pharma: Promising Yorvipath Launch and Growth Potential in Skytrofa

Ascendis Pharma (ASND – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yun Zhong from Wedbu...

Positive Outlook and Strategic Growth Catalysts Reinforce Buy Rating for Ascendis Pharma

TD Cowen lowered the firm's price target on Ascendis Pharma (ASND) to $153 from $160 and keeps a Buy rating on the shares. The firm said its target...

Ascendis Pharma price target lowered to $153 from $160 at TD Cowen

In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Ascendis Pharma (ASND – Research Report), with a pric...

Stifel Nicolaus Sticks to Its Buy Rating for Ascendis Pharma (ASND)

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Ascendis Pharma (ASND – Research Report). The c...

Bank of America Securities Sticks to Its Buy Rating for Ascendis Pharma (ASND)

Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Ascendis Pharma (ASND – Research Report) on November 15 and set a price target ...

Ascendis Pharma: Strategic Expansion and Product Launches Drive Future Growth, Outperform Rating Reaffirmed

JPMorgan's 'Analyst Focus List' – growth, income, value, short ideas

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $167.00....

Morgan Stanley Sticks to Its Hold Rating for Ascendis Pharma (ASND)

JPMorgan updates its U.S. Analyst Focus List – Adds TPR, ALRM, REG

ABBV

AGCO

ALRM

AMZN

ARMK

AVGO

BRBR

CVNA

CYBR

DAWN

DELL

DKNG

EWTX

GWRE

ISRG

KLAC

KVUE

LEGN

MNDY

MSFT

NTRA

PODD

ROIV

RVMD

SCHW

SIRI

SNDX

SPGI

SWTX

TFII

TMUS

TRGP

TVTX

ULTA

VERA

VICI

XENE

Press Releases

Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024

Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

Legal

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024

Comments

Ascendis Pharma

空売り

Ascendis Pharma (NASDAQ:ASND) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル